Effects of the LHRH antagonist Cetrorelix on the brain function in mice

Neuropeptides

Volumn 43, Issue 3, 2009, Pages 229-234

  Telegdy, Gyula ^a   Tanaka, Masaru ^a   Schally, Andrew V ^b,c  

^a UNIVERSITY OF SZEGED   (Hungary)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressive; Anxiolytic; Cetrorelix; Memory correction

Indexed keywords

AMYLOID BETA PROTEIN[25-35]; CETRORELIX;

ANIMAL EXPERIMENT; ARTICLE; BRAIN FUNCTION; CONTROLLED STUDY; DRUG EFFECT; EXPERIMENTAL TEST; FORCED SWIMMING TEST; GROOMING; LOCOMOTION; MALE; MAZE TEST; MEMORY CONSOLIDATION; MOUSE; NONHUMAN; OPEN FIELD BEHAVIOR; PASSIVE AVOIDANCE; PRIORITY JOURNAL; REARING; TAIL SUSPENSION TEST; TRANQUILIZING ACTIVITY;

ANIMALS; ANXIETY; AVOIDANCE LEARNING; BRAIN; DEPRESSION; GONADOTROPIN-RELEASING HORMONE; HORMONE ANTAGONISTS; LATERAL VENTRICLES; MICE; MOTOR ACTIVITY;

MUS;

EID: 67349134666     PISSN: 01434179     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.npep.2009.03.001     Document Type: Article

References (67)

1. Ader R., Weijnen J.A.W.M., and Moleman P. Retention of a passive avoidance response as a function of the intensity and duration of electric shock. Psychosom. Sci. 26 (1972) 126-128
2. Bajusz S., Csernus V.J., Janáky T., Bokser L., Fekete M., and Schally A.V. New antagonist of LHRH. Inhibition and potentiation of LHRH by closely related analogues. Int. J. Pept. Protein Res. 32 (1988) 425-435
3. Banks W.A., and Morley J.E. Memories are made of this: recent advances in understanding cognitive impairments and dementia. J. Gerontol. 58 (2003) AM314-AM321
4. Banks W.A., Kastin A.J., Olson G.A., and Olson R.D. Permeability of the blood-brain barrier and blood-testis barrier to LH, FSH, and albumin in younger and older mice. Neuroendocrinol. Lett. 15 (1993) 177-182
5. Barrera C.M., Banks W.A., Fasold M.B., and Kastin A.J. The bidirectional transport of LHRH across the blood-brain barrier. Am. J. Physiol. 261 (1991) E312-E318
6. Barron A., Verdile G., and Martins R.N. The role of gonadotropins in Alzheimer's disease. Endocrine 29 (2006) 257-269
7. Behre H.M., Klein B., Steinmeyer E., McGregor G.P., Voigt K., and Nieschlag E. Effective suppression of luteining hormone and testosterone by single doses of the new gonadotropin-releasing hormone antagonist Cetrorelix (SB-75) in normal men. J. Clin. Endocrinol. Metab. 75 (1992) 393-398
8. Bekker M.H.J., and van Mens-Verlust J. Anxiety disorders: sex differences in prevalence, degree, and background, but gender-neutral treatment. Gend. Med. 4 Suppl. B (2007) 178-193
9. Berry A., Tomidokoro Y., Ghiso J., and Thorton J. Human chorionic gonadotropin (a luteinizing hormone homologue) decreases spatial memory and increases brain amyloid-beta levels in female rats. Horm. Behav. 54 (2008) 143-152
10. Bokser L., Bajusz S., Groot K., and Schally A.V. Prolonged inhibition of luteinizing hormone and testosterone levels in male rats with luteinizing hormone-releasing hormone antagonist SB-75. Proc. Nat. Acad. Sci. USA 87 (1990) 7100-7104
11. Bowen R.L., Smith M.A., Harris P.L., Kubat Z., Martins R.N., Castellani R.J., Perry G., and Atwood C.S. Elevated luteinizing hormone expression with neurons vulnerable to Alzheimer's disease pathology. J. Neurosci. Res. 70 (2002) 514-518
12. Bowen R.L., Verdile G., Liu T., Parlow A.F., Perry G., Smith M.A., Martins R.N., and Atwood G. Luteinizing hormone, a reproductive regulator that modulates the processing of amyloid-β deposition. J. Biol. Chem. 279 (2004) 20539-20545
13. Breaslau N., Schultz L., and Peterson E. Sex differences in depression: role of preexisting anxiety. Psych. Res. 8 (1995) 1-12
14. Breslau N., Chilcoat H., and Schultz L.R. Anxiety disorder and the emergence of sex differences in major depression. J. Gend. Specific Med. 1 (1998) 33-39
15. Brett M., and Baxendale S. Motherhood and memory: a review. Psychoneuroendocrinology 26 (2001) 339-362
16. Bromberg J.T. A psychosocial understanding of depression in women: for the primary care physician. J. Am. Med. Women Assoc. 59 (2004) 198-206
17. Casadesus G., Atwood C.S., Zhu X., Hartzler A.W., Webber K.M., Perry G., Bowen R.L., and Smith M.A. Evidence for the role of gonadotropin hormones in the development of Alzheimer disease. Cell Mol. Life Sci. 62 (2005) 293-298
18. Casadesus G., Webber K.M., Atwood C.S., Papolla M.A., Perry G., Bowen R.L., and Smith M.A. Luteinizing hormone modulates cognition and amyloid-beta deposition in Alzheimer APP transgenic mice. Biochim. Biophys. Acta 1762 (2006) 447-452
19. Chakravarti S., Collins W.P., Forecast J.D., Newton J.R., Oram D.H., and Stud J.W. Hormonal profiles after menopause. BMJ 2 (1976) 784-787
20. Chen S., Wright J.W., and Barnes C.D. The neurochemical and behavioral effects of beta-amyloid peptide (25-35). Brain Res. 720 (1996) 54-60
21. Compton J., van Amelsvoort T., and Murphy D. Mood, cognition and Alzheimer's disease. Best Pract. Res. Clin. Obstet. Gynecol. 16 (2002) 357-370
22. Dal Forno G., Palermo M.T., Donohue J.E., Karagiozis H., Zonderman A.B., and Kawas C.H. Depressive symptoms, sex and risk for Alzheimer's disease. Ann. Neural. 57 (2005) 381-387
23. Detke M.J., RickelsLucki M., and Lucki I. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology (Berl) 121 (1995) 66-72
24. Engel J.B., and Schally A.V. Drug insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone. Nat. Clin. Pract. Endocrinol. Metab. 3 (2007) 157-167
25. Garde K. Depression-gender differences. Ugeskr Laeger 169 (2007) 2422-2425
26. Halbreich U., and Kahn L.S. Role of estrogen in the aetiology and treatment of mood disorders. CNS Drugs 15 (2001) 797-817
27. Heikkinen T., Kolesnykas G., Rissanen A., Tapiola T., Ivonene S., Wang J., Chaudhuri J., Tanila H., Miettinen R., and Puolivali J. Estrogen treatment improves spatial learning in APP + PSI mice but does not affect beta amyloid accumulation and plaque formation. Exp. Neurol. 187 (2004) 105-117
28. Holsboer F. The rational for corticotrophin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. J. Psych. Res. 33 (1999) 181-214
29. Kádár T., Telegdy G., and Schally A.V. Partial reversal of behavioral action of the agonist D-TRP-6-LH-RH by naloxone in mice. Life Sci. 46 (1990) 463-470
30. Kádár T., Telegdy G., and Schally A.V. Neuropharmacological actions of the superactive agonist analog D-TRP-6-LH-RH after peripheral injection into mice. Neuropeptides 17 (1990) 81-86
31. Khisti R.T., Chopde C.T., and Jain S.P. Antidepressant-like effect of the neurosteroid 3alpha-hydroxy-5alpha-pregnan-20-one in mice forced swim test. Pharmacol. Biochem. Behav. 67 (2000) 137-143
32. Kramer M.S., Cutler N., Fieghner J., Shrivastava R., Carman J., Sramek J.J., Reines S.A., Liu G., Snavely D., Wyatt-Knowles E., Hale J.J., Mills S.G., MacCroee M., Swain C.J., Harrison T., Hill R.G., Hefti F., Scolnick E.M., Cascieri M.A., Chicchi G.G., Sadowski S., Williams A.R., Hewson L., Smith D., Carlson E.J., Hargreaves R.J., and Rupniak N.M. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281 (1998) 1640-1645
33. Landgraf R. Neuropeptides and anxiety-related behavior. Endocrine 148 (2001) 517-533
34. Lukacs H. Rat as model for studying behavior effects of hCG. Semin. Reprod. Med. 19 (2001) 111-119
35. Lukacs H., Hiatt E.S., Lei Z.M., and Rao C.V. Peripheral and intracerebroventricular administration of human chorionic gonadotropin alters several hippocampus-associated behaviors in cyclic female rats. Horm. Behav. 29 (1995) 42-58
36. Masson G.M., Anthony F., and Chau E. Serum chorionic gonadotropin (hCG) schwangerschaftprotein 1 (SP1) progesterone and oestradiol levels in patients with nausea and vomiting in early pregnancy. Br. J. Obstet. Gynecol. 92 (1985) 211-215
37. Meethal S.V., Smith M.A., Bowen R.L., and Atwood C.S. The gonadotropin connection in Alzheimer's disease. Endocrine 26 (2005) 317-326
38. Mirowsky J. Age and the gender gap in depression. J. Health Soc. Behav. 37 (1996) 362-380
39. Molnar G., and Kassai-Bazsa Z. Gonadotropin, ACTH, prolactin, sexual steroid and cortisol levels in postmenopausal women's cerebrospinal fluid (CSF). Arch. Gerontol. Geriatr. 24 (1997) 269-280
40. Noble R.E. Depression in women. Metabolism 54 (2005) 49-52
41. Norbury R., Cutter W.J., Compton J., Robertson D.M., Craig M., Whithead M., and Murphy D.G. The neuroprotective effects of estrogen on the ageing brain. Exp. Gerontol. 38 (2003) 109-117
42. Parker G., and Hadzi-Pavlovic D. Is any female preponderance in depression secondary to a primary female preponderance in anxiety disorders?. Acta Psych. Scand. 103 (2001) 252-256
43. Pellow S., Chopin P., File S., and Briley M. Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Meth. 14 (1985) 149-167
44. Reissmann T., Schally A.V., Bouchard P., Riethmüller H., and Engel J. The LHRH antagonist Cetrorelix: a review. Human Reprod. Update 6 (2000) 322-331
45. Roesler R., Luft T., Oliveira S.H.S., Farias C.B., Almeida V.R., Quevedo J., Dal Pizzol F., Schröder N., Izquierdo I., and Schwartsmann G. Molecular mechanisms mediating gastrin-releasing peptide receptor modulation of memory consolidation in the hippocampus. Neuropharmacology 51 (2006) 350-357
46. Rosenberg R.N. The molecular, genetic basis of AD: the end of the beginning: the 2000. Wartenberg lecture. Neurology 54 (2000) 2045-2054
47. Sambamurti K., Greigh N.H., and Lahiri D.K. Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer's disease. Neuromol. Med. 1 (2002) 1-31
48. Schally A.V. LHRH analogues: their impact on reproductive medicine. Gynecol. Endocrinol. 13 (1999) 401-409
49. Schally A.V., Kastin A.J., and Arimura A. Hypothalamic FSH and LH-regulating hormone: structure, physiology and clinical studies. Fertil. Steril. 22 (1971) 703-721
50. Schally A.V., Comaru-Schally A.M., Nagy A., Kovacs M., Szepeshazi K., Plonowski A., Varga J.L., and Halmos G. Hypothalamic hormones and cancer. Front. Neuroendocrinol. 22 (2001) 248-291
51. Seeman M.V. Psychopathology in women and man: focus on female hormones. Am. J. Psych. 154 (1997) 1641-1647
52. Shors T.J., and Leuner B. Estrogen-mediated effects on depression and memory formation in females. J. Affect. Disord. 74 (2003) 85-96
53. Shumaker S.A., Legault C., Rapp S.R., Thai L., Wallace R.B., Ockene J.K., Hendrix S.L., Jones B.N., Assaf A.R., Jackson R.D., Kotchen J.M., Wassertheil-Smoller S., and Wactawski-Wende J. Estrogen plus progestin and incidence of dementia and mild cognitive impairment in postmenopausal women: the women's health initiative memory study: a randomized controlled trial. JAMA 289 (2003) 2651-2662
54. Stepanichev M.Y., Moiseeva Y.V., Lazareva N.A., Onufriev M.V., and Gulyaeva N.Y. Single intracerebroventricular administration of amyloid-beta (25-35) peptide induces impairment in short-term rather than long term memory in rats. Brain Res. Bull. 61 (2003) 197-205
55. Steru L., Chermat R., Thierry B., and Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl) 85 3 (1985) 367-370
56. Szende B., Srkalovic G., Groot K., Lapis K., and Schally A.V. Growth inhibition of mouse MXT mammary tumor by the luteinizing hormone-releasing hormone antagonist SB-75. J. Nat. Cancer Inst. 82 (1990) 517-523
57. Szontagh L., Kovacs G.L., and Telegdy G. Effect of human chorionic gonadotropin on brain monoamine content in the rats. Acta Physiol. Acad. Sci. Hung. 52 (1978) 152
58. Telegdy G., and Rózsahegyi G. Effects of gonadotropins on extinction of an avoidance conditioned reflex and exploratory behavior in the rat. Acta Physiol. Acad. Sci. Hung. 40 (1971) 209-214
59. Telegdy G., Rózsahegyi G., and Lissák K. Further data on the effects of human chorionic gonadotropin on avoidance and exploratory behavior in the rat. Acta Physiol. Acad. Sci. Hung. 40 (1971) 15-220
60. Toth P., Lukacs H., Hiatt E.S., Reid K.H., Iyer V., and Rao C.V. Adminstration of human chorionic gonadotropin affect sleep-wake phases and other associated behaviors in cycling female rats. Brain Res. 654 (1994) 181-190
61. Uday G., Pravinkumar B., Manish W., and Sudhir U. LHRH antagonist attenuates the effect of fluoxetine on marble-burying behavior in mice. Eur. J. Pharmacol. 563 (2007) 155-159
62. Umathe S.N., Bhutada P.S., Jain N.S., Shukla N.R., Mundhada Y.R., and Dixit P.V. Gonadotropin-releasing hormone agonist blocks anxiogenic-like and depressant-like effect of corticotrophin-releasing hormone in mice. Neuropeptides 42 (2008) 399-410
63. Weber K.M., Casadesus G., Bowen R.L., Perry G., and Smith M.A. Evidence for the role of luteinizing hormone in Alzheimer disease. Endocr. Metab. Immune Disord. Drug Targets 7 (2007) 300-303
64. Weinbauer G.F., and Nieschlag E. Evaluation of antigonadotropic activity of different GnRH antagonists in the non-human primate. Andrologia 25 (1993) 141-147
65. Wilson A.C., Meethal S.V., Bowen RL., and Atwood C.S. Leuprolide acetate: a drug of diverse clinical applications. Expert Opin. Investig. Drugs 16 (2007) 1851-1863
66. Wittchen H.U., and Jacobi F. Size and burden of mental disorders in Europe-a critical review and appraisal of 27 studies. Eur. Neuropsychopharmacol. 15 (2005) 357-376
67. Yamaguchi Y., and Kawashima Y. Effects of amyloid-B(25-35) on passive avoidance, radial-maze and choline acetyltransferase activity in the rat. Eur. J. Pharmacol. 412 (2001) 265-272